NICOPASS
Pierre Fabre Medicament
| Research |
OneLook
Acronym Finder
|
| Serial Number | 85522881 |
| Registration Number | 4352453 |
| Mark Drawing Code | 4000: Illustration: Drawing with word(s)/letter(s)/number(s) in Block form |
| Domestic Representative | G. Patrick SAGE |
| Attorney Name | G. Patrick SAGE |
| Attorney Docket Number | PF FTM 498 |
| Law Office Assigned | M10 |
| Employee Name | KHOURI, SANI PHILIPPE |
Timeline
| 2012-01-23 | Application Filed |
| 2013-04-02 | Published for Opposition |
| 2013-06-18 | Location: PUBLICATION AND ISSUE SECTION |
| 2013-06-18 | Status: Live/Registered |
| 2013-06-18 | Trademark Registered |
| 2018-07-08 | Transaction Date |
Trademark Applicants & Owners
| Owner: |  PIERRE FABRE MEDICAMENT |
| Entity Statement | société par actions simplifiée (sas) |
| Address | 45 Place Abel Gance BOULOGNE BILLANCOU FR 92100 |
| Legal Entity Type | |
| Legal Entity State | FR |
Documents
Click the blue "Refresh" button to load certificates, specimines, application, and other documents.
Attorney of Record
Good, Services, and Codes
| International Codes: | 5 |
| U.S. Codes: | 006,018,044,046,051,052 |
| Type Code | Type |
|---|---|
| GS0051 | Pharmaceutical preparations and substances, namely, smoking cessation preparation; dietetic foods adapted for medical use intended to break the habit of smoking |
Trademark Filing History
| Description | Date | Event Coding |
|---|---|---|
| NEW APPLICATION ENTERED IN TRAM | 2012-01-26 | 1 NWAP I:Incoming Correspondence |
| NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM | 2012-01-26 | 2 NWOS I:Incoming Correspondence |
| NOTICE OF PSEUDO MARK MAILED | 2012-01-27 | 3 MPMK O:Outgoing Correspondence |
| ASSIGNED TO EXAMINER | 2012-02-24 | 4 DOCK D:Assigned to Examiner |
| NON-FINAL ACTION WRITTEN | 2012-02-24 | 5 CNRT R:Renewal |
| NON-FINAL ACTION MAILED | 2012-02-27 | 6 CNRT F:First Action |
| TEAS RESPONSE TO OFFICE ACTION RECEIVED | 2012-08-21 | 7 TROA I:Incoming Correspondence |
| CORRESPONDENCE RECEIVED IN LAW OFFICE | 2012-08-21 | 8 CRFA I:Incoming Correspondence |
| TEAS/EMAIL CORRESPONDENCE ENTERED | 2012-08-22 | 9 TEME I:Incoming Correspondence |
| SUSPENSION LETTER WRITTEN | 2012-09-11 | 10 CNSL R:Renewal |
| LETTER OF SUSPENSION MAILED | 2012-09-12 | 11 CNSL S: |
| APPROVED FOR PUB - PRINCIPAL REGISTER | 2013-02-08 | 12 CNSA O:Outgoing Correspondence |
| ASSIGNED TO LIE | 2013-02-22 | 13 ALIE A:Allowance for Publication |
| LAW OFFICE PUBLICATION REVIEW COMPLETED | 2013-02-22 | 14 PREV O:Outgoing Correspondence |
| NOTICE OF PUBLICATION | 2013-03-13 | 15 NPUB O:Outgoing Correspondence |
| PUBLISHED FOR OPPOSITION | 2013-04-02 | 16 PUBO A:Allowance for Publication |
| REGISTERED-PRINCIPAL REGISTER | 2013-06-18 | 17 R.PR A:Allowance for Publication |
| CANCELLED SEC. 8 (6-YR) | 2020-01-24 | 18 C8.. O:Outgoing Correspondence |
Similar Marks
Mark Image Registration | Serial | Company Trademark Application Date |
|---|---|
 NICOPASS 85522881 4352453 Live/Registered |
PIERRE FABRE MEDICAMENT 2012-01-23 |
 NICOPASS 76600865 3047824 Dead/Cancelled |
PIERRE FABRE MEDICAMENT 2004-07-07 |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.
| 